Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results
November 15, 2023 09:00 ET
|
Oncotelic Therapeutics, Inc.
R&D cost remains essentially unchanged, while continuing expansion of our OT-101 clinical programs through our joint venture (“JV”)G&A cost significantly lower by over approximately $0.5...